ArticleJournal of pharmaceutical health care and sciences2025
Anemia in heart failure: evidence from a three-year cross-sectional study in Sudan.
Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Burden and clinical impact of anemia in heart failure: insights from a large observational cohort in Saudi Arabia.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnemia is a frequent complication of heart failure (HF) that exacerbates cardiac dysfunction and worsens prognosis. However, its exact burden and treatment patterns in Sudan HF remain unknown. Thus, this study aimed to describe the prevalence, characteristics, and management of anemia among Sudanese HF patients.
methodsWe conducted a retrospective cross-sectional study of adult HF patients admitted to Wad Medani Heart Center, Sudan, over three years. Baseline hemoglobin (Hb) was defined as the first measurement within 24-48 h of index admission. Only patients with evaluable baseline Hb were included in the analytic cohort.
resultsOf 557 HF patients, 266 (47.8% of full cohort; 51% of analytic cohort) were anemic (mean Hb 10.68 ± 1.51 g/dL). The mean age was 60.4 ± 18 SD, 136 (51%) were females, 114 (43%) aged more than 65 years, and 77 (28%) had prior HF admissions. Hypertension 136 (51%), diabetes 91 (34%) and chronic kidney disease 75 (28%) were other comorbidities. Anemia was most prevalent in the HF with mid-range ejection fraction (HFmrEF) cohort 134 (50.4%), followed by HF with reduced ejection fraction (HFrEF) 71 (26.7%) and HF with a preserved ejection fraction (HFpEF) 61 (22.9%). Among anemic HF patients, only 77 (29%) received anemia management. Of those, 28(36.4%) received blood transfusions, and 34 (44.2%) received iron supplementation.
conclusionsNealy half of HF patients were anemic, particularly older and those with HFmrEF, and treatment was suboptimal. Incorporating routine anemia screening and standardized management into HF care protocols is essential to enhance clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.